This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Periasamy, M. Search for Related Content PubMed PubMed Citation Articles by Periasamy, M. Related Collections Apoptosis Calcium cycling/excitation-contraction coupling Gene expression Hypertrophy Gene therapy

(Circulation Research. 2001;88:373.)
© 2001 American Heart Association, Inc.

Editorial

Adenoviral-Mediated SERCA Gene Transfer Into Cardiac Myocytes

How Much Is Too Much?

Muthu Periasamy

From the College of Medicine, University of Cincinnati, Cincinnati, Ohio.

Correspondence to Muthu Periasamy, PhD, College of Medicine, University of Cincinnati, 231 Albert-Sabin Way, Cincinnati, OH 45267-0542. E-mail muthu.periasamy@uc.edu

Key Words: excitation-contraction coupling • heart failure • SERCA-SR Ca²⁺ ATPase • gene transfer

	Introduction

 
In the last decade, a great deal of attention has been focused on adenoviral-mediated gene transfer into somatic cells as a possible therapeutic approach. Somatic gene transfer into postmitotic cells (such as cardiomyocytes) provides a very powerful means to deliver the protein of interest, which is either functionally defective or missing because of loss of gene expression.

In recent years, gene therapy for heart failure has gained considerable interest, mainly because of improvements in vector technology, cardiac gene delivery, and a better understanding of the molecular basis of heart failure.^{1 2}

	Ca2+ Handling and Heart Failure

 
Heart failure provides an attractive candidate for gene therapy, because several targets have been identified as either functionally impaired or defective. Studies using animal models and failing human hearts have identified several abnormalities that affect excitation-contraction coupling. In particular, changes at the level of sarcolemmal/sarcoplasmic reticulum Ca²⁺ transport and contractile proteins are thought to contribute to depressed contractile function. Cardiomyocytes from failing animal and human hearts reveal abnormal Ca²⁺ homeostasis, such as reduced sarcoplasmic reticulum (SR) Ca²⁺ release, elevated diastolic Ca²⁺, and reduced rate of Ca²⁺ removal.^{3 4 5} There is strong evidence that reduced expression or activity of the SR Ca²⁺ ATPase (SERCA) and increased expression of Na⁺-Ca²⁺ exchanger are key changes contributing to alterations in calcium homeostasis in the heart.^{6 7 8 9 10} It is also believed that abnormalities in calcium cycling are responsible for blunting of the frequency potentiation of contractile force in the failing human heart.¹¹ Thus, SR Ca²⁺ ATPase plays a dominant role in removing cytosolic Ca²⁺ and . . . [Full Text of this Article]

This article has been cited by other articles:

				D. J. Thuerauf, H. Hoover, J. Meller, J. Hernandez, L. Su, C. Andrews, W. H. Dillmann, P. M. McDonough, and C. C. Glembotski Sarco/endoplasmic Reticulum Calcium ATPase-2 Expression Is Regulated by ATF6 during the Endoplasmic Reticulum Stress Response. INTRACELLULAR SIGNALING OF CALCIUM STRESS IN A CARDIAC MYOCYTE MODEL SYSTEM J. Biol. Chem., December 14, 2001; 276(51): 48309 - 48317. [Abstract] [Full Text] [PDF]